2024
Rheumatoid arthritis and peripartum cardiovascular complications: focusing on non-traditional cardiovascular risk factors to improve maternal outcomes
Goldstein S, Lindley K. Rheumatoid arthritis and peripartum cardiovascular complications: focusing on non-traditional cardiovascular risk factors to improve maternal outcomes. European Heart Journal 2024, 45: 1537-1539. PMID: 38713839, DOI: 10.1093/eurheartj/ehae164.Peer-Reviewed Original ResearchConceptsCardiovascular risk factorsMaternal cardiovascular risk factorsPre-conception counsellingNon-traditional cardiovascular risk factorsCardio-obstetricsAdverse pregnancy outcomesRisk factorsPregnancy outcomesCardiovascular adverse outcomesAdverse outcomesMaternal outcomesRheumatoid arthritisMaternal cardiovascular complicationsCardiovascular complicationsCounselingOutcomesPregnancyRiskArthritisPracticeFactorsComplex Congenital Heart Disease in the Adult
Goldstein S, Krasuski R. Complex Congenital Heart Disease in the Adult. Annual Review Of Medicine 2024, 75: 493-512. PMID: 38285514, DOI: 10.1146/annurev-med-050922-052324.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCongenital heart diseaseAdult congenital heart diseaseComplex congenital heart diseaseHeart diseaseSevere birth defectsStructural abnormalitiesBirth defectsComplex lesionsFrequent causeHigh riskImprove outcomesPediatric outcomesHeterogeneous groupPalliative interventionsCardiovascular systemDiseaseAdultsOutcomesComplications
2023
Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
Goldstein S, Kennedy K, Friedman D, Al‐Khatib S, Wang A. Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy. Journal Of The American Heart Association 2023, 12: e029293. PMID: 37586066, PMCID: PMC10492935, DOI: 10.1161/jaha.122.029293.Peer-Reviewed Original ResearchConceptsNew York Heart Association classPrimary prevention implantable cardioverter-defibrillatorHistory of nonsustained ventricular tachycardiaImplantable cardioverter-defibrillatorImplantable cardioverter-defibrillator utilizationNonsustained ventricular tachycardiaHypertrophic cardiomyopathyAssociation classVentricular tachycardiaOlder patientsCardioverter-defibrillatorLeft ventricular ejection fractionRisk factorsNational Cardiovascular Data Registry ICD RegistryFactors associated with mortalityImplantable cardioverter-defibrillator implantationAssociated with postdischarge mortalityVentricular ejection fractionPrevalence of risk factorsSudden cardiac deathPostdischarge hospitalizationAssociated with hospitalizationCenters for MedicareEjection fractionICD RegistryAntihypertensives in Pregnancy
Denoble A, Goldstein S, Pettker C. Antihypertensives in Pregnancy. Obstetrics And Gynecology Clinics Of North America 2023, 50: 39-78. PMID: 36822710, DOI: 10.1016/j.ogc.2022.10.008.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSignificant maternal morbidityTreatment of hypertensionAmniotic fluid volumeHypertensive disordersMaternal morbidityPregnant patientsFetal growthCurrent guidelinesEfficacy dataAvailable safetyPregnancyAntihypertensivesFluid volumeClose supervisionHypertensionMorbidityPatientsPostpartumMortalityAvailable dataDiagnosis
2022
Prospective Observational Study of N-terminal Pro–Brain Natriuretic Peptide Levels in Obese and Nonobese Women during Pregnancy
Denoble A, Moyett J, Goldstein S, Ward CC, Truong T, Erkanli A, James A, Grotegut C. Prospective Observational Study of N-terminal Pro–Brain Natriuretic Peptide Levels in Obese and Nonobese Women during Pregnancy. American Journal Of Perinatology 2022, 40: 467-474. PMID: 35973801, PMCID: PMC10168705, DOI: 10.1055/a-1925-1532.Peer-Reviewed Original ResearchConceptsNT-proBNP levelsBody mass indexProspective observational studyObese patientsNonobese patientsNT-proBNPWeeks postpartumObservational studyN-terminal pro-brain natriuretic peptide levelsN-terminal pro-brain natriuretic peptidePro-brain natriuretic peptide levelsLinear mixed effects modelsLower NT-proBNP levelsHigher systolic blood pressurePro-brain natriuretic peptidePregnant peopleNatriuretic peptide levelsSignificant medical comorbiditiesTime pointsSystolic blood pressureMixed effects modelsEffects modelLogNT-proBNPPP elevationHypertensive disordersComparison of severe maternal morbidity in pregnancy by modified World Health Organization Classification of maternal cardiovascular risk
Denoble AE, Goldstein SA, Wein LE, Grotegut CA, Federspiel JJ. Comparison of severe maternal morbidity in pregnancy by modified World Health Organization Classification of maternal cardiovascular risk. American Heart Journal 2022, 250: 11-22. PMID: 35526569, PMCID: PMC9836743, DOI: 10.1016/j.ahj.2022.04.009.Peer-Reviewed Original ResearchConceptsSevere maternal morbidityWorld Health Organization classificationDelivery hospitalizationsCardiac diagnosisMaternal morbidityOrganization classificationMaternal cardiovascular riskNationwide Readmissions DatabaseRisk of deathSevere cardiac diseaseWeighted national estimateMWHO classificationDelivery admissionCardiovascular riskPregnant patientsSecondary outcomesPrimary outcomeRetrospective studyYear postpartumPregnancy counselingPrimary exposureMonths postpartumNationwide databaseCardiac diseaseElevated riskPulmonary Hypertension in Adults with Congenital Heart Disease
Goldstein S, Krasuski R. Pulmonary Hypertension in Adults with Congenital Heart Disease. Cardiology Clinics 2022, 40: 55-67. PMID: 34809917, DOI: 10.1016/j.ccl.2021.08.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPAH-CHDPulmonary arterial hypertension related to congenital heart diseaseSystemic-to-pulmonary shuntAssociated with significant morbidityCongenital heart diseasePulmonary vascular resistancePulmonary vascular remodelingShunt reversalEisenmenger syndromePulmonary hypertensionCentral cyanosisPrimary management strategySignificant morbidityMedical therapySevere elevationVascular resistanceDefect closureSevere phenotypeVascular remodelingHeart diseasePathological processesShuntCyanosisAdultsHypoxemia
2021
Pregnancy in a woman with congenitally corrected transposition of the great arteries
Goldstein S, Sorenson L, Chapa J, Krasuski R. Pregnancy in a woman with congenitally corrected transposition of the great arteries. Cleveland Clinic Journal Of Medicine 2021, 88: 228-236. PMID: 33795247, DOI: 10.3949/ccjm.88a.20136.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization
Goldstein S, Li S, Lu D, Matsouaka R, Rymer J, Fonarow G, de Lemos J, Peterson E, Pokorney S, Wang T, Al-Khatib S. Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. The American Journal Of Cardiology 2020, 138: 26-32. PMID: 33068540, DOI: 10.1016/j.amjcard.2020.09.056.Peer-Reviewed Original ResearchMeSH KeywordsAftercareAge FactorsAgedAged, 80 and overCardiologyCoronary Artery BypassDeath, Sudden, CardiacDefibrillators, ImplantableFemaleHeart FailureHumansMaleMedicareMortalityMyocardial InfarctionMyocardial RevascularizationPatient ReadmissionPercutaneous Coronary InterventionProportional Hazards ModelsSex FactorsStroke VolumeTachycardia, VentricularUnited StatesVentricular FibrillationConceptsImplantable cardioverter-defibrillator implantationImplantable cardioverter-defibrillatorIn-hospital ventricular arrhythmiasLow ejection fractionAssociated with ICD implantationEjection fractionVentricular arrhythmiasICD implantationCoronary revascularizationCABG-treated patientsPCI-treated patientsAssociated with lower mortalityCardiology follow-upIn-hospital revascularizationAll-cause mortalityAssociated with higher likelihoodICD utilizationHeart failure readmissionHeart failureYear of revascularizationCardioverter-defibrillatorRevascularization strategyMedicare claimsRevascularizationPatientsCauses of Death and Cardiovascular Comorbidities in Adults With Congenital Heart Disease
Goldstein S, D’Ottavio A, Spears T, Chiswell K, Hartman R, Krasuski R, Kemper A, Meyer R, Hoffman T, Walsh M, Sang C, Paolillo J, Li J. Causes of Death and Cardiovascular Comorbidities in Adults With Congenital Heart Disease. Journal Of The American Heart Association 2020, 9: e016400. PMID: 32654582, PMCID: PMC7660712, DOI: 10.1161/jaha.119.016400.Peer-Reviewed Original ResearchConceptsCongenital heart diseaseSevere congenital heart diseaseMedian ageNonsevere CHDPresence of cardiovascular comorbiditiesHeart diseaseCardiovascular risk factorsNon-CHD causesIschemic heart diseaseElectronic medical record dataDeath certificate dataCause of deathNonsevere diseaseContemporary cohortValvular lesionsCardiovascular comorbidityCardiovascular comorbiditiesResults PatientsCardiovascular deathMedical record dataRisk factorsSevere groupLesion severityPatientsCertificate data
2019
Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE
Zeitler E, Friedman D, Loring Z, Campbell K, Goldstein S, Wegermann Z, Schutz J, Smith N, Black-Maier E, Al-Khatib S, Piccini J. Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. Heart Rhythm 2019, 17: 447-454. PMID: 31561032, PMCID: PMC7519585, DOI: 10.1016/j.hrthm.2019.09.024.Peer-Reviewed Original ResearchConceptsSubcutaneous implantable cardioverter-defibrillatorS-ICD complicationsImplantable cardioverter-defibrillatorS-ICDInappropriate shocksCardioverter-defibrillatorSystem removalLow rate of complicationsProcedure-related complicationsRate of complicationsFood and Drug Administration's ManufacturerManufacturer and User Facility Device ExperienceUser Facility Device ExperiencePatient selectionFollow-upComplicationsTransvenous devicesVentricular fibrillationDevice-device interactionsClinical experiencePatientsDefibrillation failureImplantation techniqueSystem reprogrammingSystem revisionCharacteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial)
Goldstein S, Green J, Huber K, Wojdyla D, Lopes R, Alexander J, Vinereanu D, Wallentin L, Granger C, Al-Khatib S. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). The American Journal Of Cardiology 2019, 124: 1406-1412. PMID: 31474328, PMCID: PMC7194994, DOI: 10.1016/j.amjcard.2019.07.046.Peer-Reviewed Original ResearchConceptsThyroid disease historyThyroid diseaseAtrial fibrillationDisease historyThromboembolic eventsClinical outcomesOutcomes of atrial fibrillationHistory of thyroid diseaseBaseline characteristics of patientsCox modelBenefits of apixabanOther Thromboembolic EventsCharacteristics of patientsEffects of anticoagulantsAdjusted hazard ratiosBaseline characteristicsCompare outcomesHazard ratioThyroidApixabanPatientsRandomized treatmentWarfarinHypothyroidismDisease
2018
Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes
Goldstein S, Mentz R, Hellkamp A, Randolph T, Fonarow G, Hernandez A, Yancy C, Al‐Khatib S. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. Clinical Cardiology 2018, 42: 256-263. PMID: 30548280, PMCID: PMC6386168, DOI: 10.1002/clc.23135.Peer-Reviewed Original ResearchConceptsCardiac resynchronization therapy implantationCardiac resynchronization therapyHF re-hospitalizationHeart failureRe-hospitalizationHF hospitalizationCardiac resynchronization therapy device implantationOutcome of all-cause mortalityTime of CRT implantationAssociated with clinical outcomesAssociated with similar benefitsAll-cause mortalityAssociated with lower ratesHeart failure patientsCRT implantationResynchronization therapyClinical outcomesHF patientsDevice implantationFailure patientsCenters for MedicarePatientsDelayed implantationReduce mortalityMedicaid Services data
2017
Congenital and Acquired Valvular Heart Disease in Pregnancy
Goldstein S, Ward C. Congenital and Acquired Valvular Heart Disease in Pregnancy. Current Cardiology Reports 2017, 19: 96. PMID: 28840470, DOI: 10.1007/s11886-017-0910-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsValvular heart diseaseHeart diseaseRisk of pregnancy-related complicationsManagement of valvular heart diseaseWomen of childbearing agePregnancy-related complicationsAcquired valvular heart diseaseRheumatic heart diseaseValvular abnormalitiesCongenital abnormalitiesCase reportSymptomatic diseaseChildbearing ageRegurgitant lesionsHemodynamic effectsPatient populationPregnancyPercutaneous interventionStenotic lesionsRefractory symptomsHigh riskObservational studyReviewThe numberDiseaseAbnormalitiesRelationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes
Goldstein S, Newby L, Cyr D, Neely M, Lüscher T, Brown E, White H, Ohman E, Roe M, Hamm C. Relationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. Journal Of The American Heart Association 2017, 6: e005334. PMID: 28400368, PMCID: PMC5533023, DOI: 10.1161/jaha.116.005334.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedBiomarkersChi-Square DistributionClopidogrelDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLinear ModelsMaleMiddle AgedMultivariate AnalysisNon-ST Elevated Myocardial InfarctionPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProportional Hazards ModelsRisk FactorsTiclopidineTime FactorsTreatment OutcomeTroponinUp-RegulationConceptsNon-ST-segment elevation ACS patientsLong-term ischemic eventsACS patientsDiabetes mellitus prevalenceTroponin levelsBody mass indexStatistically significant heterogeneityGRACE risk scoreHeterogeneity of treatment effectsIschemic eventsIndex ACS eventACS eventsNon-ST-segment elevation ACSMedically managed patientsComposite end pointLong-term outcomesMass indexTreatment effectsRisk scorePeak troponin valuesPercutaneous coronary interventionSignificant heterogeneityStatistically significant differenceManaging patientsPeak troponin
2016
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials
Kragholm K, Goldstein S, Yang Q, Lopes R, Schulte P, Bernacki G, White H, Mahaffey K, Giugliano R, Armstrong P, Harrington R, Tricoci P, Van de Werf F, Alexander J, Alexander K, Newby L. Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials. Circulation 2016, 133: 1560-1573. PMID: 26957532, PMCID: PMC4856566, DOI: 10.1161/circulationaha.115.017299.Peer-Reviewed Original ResearchConceptsIncrease evidence-based careEvidence-based careClinical characteristicsClinical trialsAcute coronary syndrome trialsTranslation of clinical trialNon-ST segment elevation acute coronary syndromeNon-ST segment elevationPhase III clinical trialsPost-myocardial infarction mortalityIII clinical trialsClinical trial enrollmentInfarction mortalityAcute coronary syndromeClinical trial populationsAge strataGeneral populationTrial enrollmentIn-hospitalCoronary syndromeOlder patientsIncreased comorbiditiesTrial backgroundTrial populationEnrollment
2015
Acute Coronary Syndrome
Fanaroff A, Rymer J, Goldstein S. Acute Coronary Syndrome. JAMA 2015, 314: 1990-1990. PMID: 26547478, DOI: 10.1001/jama.2015.12743.Peer-Reviewed Original ResearchDoes This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review
Fanaroff A, Rymer J, Goldstein S, Simel D, Newby L. Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review. JAMA 2015, 314: 1955-1965. PMID: 26547467, DOI: 10.1001/jama.2015.12735.Peer-Reviewed Original ResearchConceptsDiagnosis of acute coronary syndromeAcute coronary syndromeHigh-risk rangeRisk scoreProspective study of diagnostic test accuracyHEART scoreEmergency departmentChest painCardiac Society of AustraliaProbability of acute coronary syndromeTIMI scoreStudies of diagnostic test accuracyCoronary syndromePhysical examinationRisk factorsDiagnosing ACSLikelihood ratioSuspected acute coronary syndromeAcute chest painAbnormal stress testLow-risk patientsHigh-risk patientsTIMI risk scoreCardiac-specific troponinEvidence of ischemia